The global healthcare industry is witnessing unprecedented investment in hyperparathyroidism research and development, as stakeholders recognize the significant clinical and economic burden of this endocrine disorder. With over 100,000 new cases diagnosed annually in the United States alone, hyperparathyroidism represents a substantial market opportunity for pharmaceutical companies and medical device manufacturers. Economic Impact and Healthcare Read.